XBiotech (NASDAQ:XBIT) and Inspyr Therapeutics (OTCMKTS:NSPX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.
Valuation & Earnings
This table compares XBiotech and Inspyr Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
Insider & Institutional Ownership
12.1% of XBiotech shares are held by institutional investors. 33.4% of XBiotech shares are held by insiders. Comparatively, 0.0% of Inspyr Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Volatility and Risk
XBiotech has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, Inspyr Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.
This table compares XBiotech and Inspyr Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings for XBiotech and Inspyr Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
XBiotech currently has a consensus price target of $28.00, suggesting a potential upside of 28.56%. Given XBiotech’s higher probable upside, equities research analysts clearly believe XBiotech is more favorable than Inspyr Therapeutics.
XBiotech beats Inspyr Therapeutics on 5 of the 8 factors compared between the two stocks.
XBiotech Company Profile
XBiotech Inc., a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company’s lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection and influenza diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Inspyr Therapeutics Company Profile
Inspyr Therapeutics, Inc., an early-stage pharmaceutical company, focuses on the discovery and development of prodrug cancer therapeutics in the United States. It develops cancer therapeutics for the treatment of solid tumors, including brain, liver, prostate, and other cancers. The company’s lead drug candidate is mipsagargin, which has completed an open label single arm Phase II clinical trial in patients with advanced hepatocellular carcinoma or liver cancer. The company was formerly known as GenSpera Inc. and changed its name to Inspyr Therapeutics, Inc. in August 2016. Inspyr Therapeutics, Inc. was founded in 2003 and is based in Westlake Village, California.
Receive News & Ratings for XBiotech Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for XBiotech and related companies with MarketBeat.com’s FREE daily email newsletter.